Affinage

PLCL1

Inactive phospholipase C-like protein 1 · UniProt Q15111

Length
1095 aa
Mass
122.7 kDa
Annotated
2026-04-28
94 papers in source corpus 22 papers cited in narrative 23 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PLCL1 (also called PRIP-1) is a catalytically inactive phospholipase C-δ1-like scaffold protein that integrates inositol phosphate signaling, protein phosphatase targeting, and SNARE-dependent exocytosis to regulate calcium dynamics, receptor trafficking, and cell fate across diverse tissues. Its PH domain binds Ins(1,4,5)P3 and PI(4,5)P2 to attenuate IP3-mediated Ca²⁺ release and to compete with PI3K for PI(4,5)P2 substrate, thereby suppressing AKT signaling, cell cycle progression, and fibrosis via the PI3K–AKT–MST2–YAP axis (PMID:10581172, PMID:15468068, PMID:33743346, PMID:41680862). PLCL1 functions as a PKA-regulated phospho-switch that binds PP1 and PP2A in a mutually exclusive manner to control dephosphorylation of GABAA receptor β-subunits, SNAP-25, and hormone-sensitive lipase, while its C2 domain directly engages syntaxin 1 and SNAP-25 to inhibit SNARE complex assembly and exocytosis (PMID:23911386, PMID:22311984, PMID:23341457, PMID:24945349). Through GABARAP sequestration it restrains KIF5B-driven insulin vesicle transport, and through modulation of BMP–Smad signaling it negatively regulates osteoblast differentiation, while promoting osteoclastogenesis via calcineurin–NFATc1 (PMID:24812354, PMID:21757756, PMID:28341745).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1999 High

    Establishing that PLCL1 is a catalytically dead PLC-δ homolog whose PH domain binds IP3 and PIP2 resolved the paradox of a PLC-like protein that cannot hydrolyze lipids and reframed it as a signaling scaffold.

    Evidence Biochemical binding assays, GFP-fusion imaging, and active-site mutagenesis in COS7 and myoblast cells

    PMID:10581172

    Open questions at the time
    • No structural basis for catalytic inactivity beyond sequence comparison
    • Endogenous protein levels and tissue distribution incompletely mapped
  2. 2002 High

    Identification of PP1, PP2A, and GABARAP as direct binding partners of PLCL1 established it as a phosphatase-targeting scaffold with a role in GABAA receptor regulation, explaining altered GABAergic transmission in KO mice.

    Evidence Yeast two-hybrid, pull-down, surface plasmon resonance, PP1 activity assays, and PRIP-1 knockout mouse electrophysiology

    PMID:11979730 PMID:12467885

    Open questions at the time
    • Structural basis for simultaneous versus mutually exclusive PP1/GABARAP binding unknown
    • In vivo stoichiometry of PLCL1–PP1 complex not determined
  3. 2005 High

    Demonstrating that PLCL1 shields IP3 from 5-phosphatase degradation in neurons showed it sustains IP3 pools rather than simply sequestering them, providing a mechanism for the reduced Ca²⁺ responses in KO neurons.

    Evidence PRIP-1 KO mouse neurons with Ca²⁺ imaging, [³H]IP3 labeling, and 5-phosphatase activity assays

    PMID:15468068

    Open questions at the time
    • Identity of the 5-phosphatase isoform protected by PLCL1 not fully resolved
    • Whether PLCL1 also modulates IP3 receptor gating directly remains untested
  4. 2006 High

    Revealing that PKA phosphorylation of PLCL1 triggers a PP1-to-PP2A switch established a phospho-dependent scaffold mechanism that temporally controls GABAA receptor β3-subunit dephosphorylation and surface expression.

    Evidence Site-directed mutagenesis, reconstituted binding with purified proteins, and double-KO mouse cortical neurons with forskolin stimulation

    PMID:16404143 PMID:16854455 PMID:17690529

    Open questions at the time
    • Kinetics of the PP1/PP2A switch in intact synapses not measured
    • Whether other kinases besides PKA trigger the switch is unknown
  5. 2011 High

    Showing that PLCL1 loss enhances BMP-induced Smad1/5/8 phosphorylation and increases bone mineral density extended its scaffold role beyond GABAergic signaling into TGF-β superfamily regulation of osteoblast differentiation.

    Evidence PRIP-KO mouse micro-CT bone phenotyping and primary calvaria osteoblast Smad phosphorylation assays

    PMID:21757756 PMID:25981537

    Open questions at the time
    • Direct physical interaction between PLCL1 and Smad6 or BMP receptors not shown
    • Mechanism of PLCL1-facilitated Smad6 methylation relies on poorly characterized inhibitor
  6. 2012 High

    Discovery that the C2 domain binds syntaxin 1 and SNAP-25 to inhibit SNARE complex formation, and that PLCL1 recruits PP1 to dephosphorylate SNAP-25, established a dual mechanism for suppressing regulated exocytosis.

    Evidence In vitro binding, co-IP, SNARE complex gel assay, and noradrenalin secretion from PC12 cells with PP1-binding mutant controls

    PMID:22311984 PMID:23341457

    Open questions at the time
    • Whether both C2-domain SNARE binding and PP1-mediated SNAP-25 dephosphorylation operate in the same cell type simultaneously is unclear
    • Physiological relevance for neurotransmitter release in vivo not tested
  7. 2013 High

    Biochemical reconstitution of mutually exclusive PP1 and PP2A binding to PLCL1 in living cells confirmed the phospho-switch model and generalized it beyond GABAA receptors.

    Evidence Pull-down with purified proteins, mutagenesis, and immunoprecipitation from neuronal cells treated with forskolin/isoproterenol

    PMID:23911386

    Open questions at the time
    • Crystal structure of PLCL1–PP1 and PLCL1–PP2A interfaces not available
    • Full inventory of substrates regulated by the switch is incomplete
  8. 2014 High

    Showing that PLCL1 sequesters GABARAP from insulin vesicles to limit KIF5B-driven transport, and separately translocates PP2A to lipid droplets to reduce lipolysis, broadened its scaffold functions to metabolic regulation in pancreatic β-cells and adipocytes.

    Evidence siRNA knockdown in MIN6 cells with live imaging of insulin vesicles; PRIP-KO mouse adipose tissue fractionation and lipolysis assays

    PMID:24812354 PMID:24945349

    Open questions at the time
    • Whether PLCL1–GABARAP interaction is regulated by phosphorylation like PP1 binding is unknown
    • Relative contribution of PLCL1 to whole-body lipid homeostasis versus other regulators not quantified
  9. 2017 High

    Demonstration that PLCL1 promotes osteoclastogenesis through calcium–calcineurin–NFATc1 signaling, with rescue by exogenous Ca²⁺, showed its IP3/Ca²⁺ buffering function operates in opposite directions in osteoblasts versus osteoclasts.

    Evidence PRIP-KO mouse orthodontic tooth movement model, osteoclast differentiation, calcineurin activity, and Ca²⁺ imaging with rescue

    PMID:28341745

    Open questions at the time
    • How PLCL1 simultaneously promotes and inhibits Ca²⁺ signaling in different bone lineages is mechanistically unresolved
  10. 2019 Medium

    Finding that PLCL1 stabilizes UCP1 by reducing its ubiquitination in clear cell renal carcinoma introduced a non-canonical function in protein quality control and lipid browning distinct from its classical IP3/phosphatase roles.

    Evidence PLCL1 overexpression in ccRCC cells, ubiquitination assay, lipid droplet imaging, and tumor xenograft

    PMID:31131187

    Open questions at the time
    • The E3 ligase counteracted by PLCL1 is not identified
    • Whether PLCL1 directly binds UCP1 or acts indirectly through signaling is unresolved
    • Single-lab finding awaits independent confirmation
  11. 2021 High

    Demonstrating that PLCL1 competes with PI3K for PIP2 substrate to suppress AKT/GSK3β/cyclin D1 signaling and tumor growth unified its PH-domain lipid-binding function with tumor-suppressive activity.

    Evidence PLCL1 overexpression and knockdown in MCF-7 cells, PIP3 immunofluorescence, cell cycle analysis, and xenograft model

    PMID:33743346

    Open questions at the time
    • Direct measurement of PIP2 consumption or PI3K displacement at the membrane not performed
    • Generality across cancer types beyond breast cancer not established at the time
  12. 2025 High

    Linking PLCL1 loss to AKT-driven MST2 phosphorylation and YAP nuclear translocation in a fibrosis model connected its PIP2-sequestration function to the Hippo pathway and organ fibrosis in vivo.

    Evidence PRIP-KO mouse angiotensin II fibrosis model, MEF TGF-β1 treatment, AKT/MST2/YAP western blots, and YAP nuclear localization

    PMID:41680862

    Open questions at the time
    • Whether PLCL1 directly interacts with MST2 or YAP or acts entirely through AKT is unknown
    • Therapeutic potential of restoring PLCL1 in fibrosis not assessed

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis for PLCL1's mutually exclusive PP1/PP2A binding, the mechanism by which PLCL1 reduces UCP1 ubiquitination, and whether its calcium-regulatory function in quiescent HSCs operates through IP3 sequestration, PIP2 competition, or both.
  • No crystal or cryo-EM structure of PLCL1 or its complexes exists
  • HSC calcium regulatory mechanism is from a single preprint and awaits peer review
  • Complete substrate inventory for PLCL1-scaffolded PP1/PP2A is lacking

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 7 GO:0098772 molecular function regulator activity 6 GO:0008289 lipid binding 4
Localization
GO:0005829 cytosol 2 GO:0005783 endoplasmic reticulum 1 GO:0005811 lipid droplet 1
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-112316 Neuronal System 4 R-HSA-5653656 Vesicle-mediated transport 3 R-HSA-1266738 Developmental Biology 2 R-HSA-1430728 Metabolism 2
Partners
DEPP1GABARAPGABRB3GABRG2PPP1CAPPP2CASNAP25STX1A

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 PLCL1 (PLC-L2) was identified as a catalytically inactive phospholipase C-like protein; its PH domain binds strongly to PI(4,5)P2 and Ins(1,4,5)P3, and it localizes predominantly to perinuclear/endoplasmic reticulum areas in myoblast, myotube, and COS7 cells, suggesting a role in regulating Ins(1,4,5)P3 signaling near the ER. Biochemical binding assays, GFP-fusion live-cell imaging, subcellular fractionation, mutagenesis of catalytic residues Biochemical and biophysical research communications High 10581172
2002 PRIP-2 (PLCL2 paralog, used for comparison) and PRIP-1 (PLCL1 ortholog) both bind Ins(1,4,5)P3 and its parent lipid PI(4,5)P2 via their PH domains, interact with protein phosphatase 1 (PP1) and GABARAP, and are expressed in overlapping brain regions; PRIP-1 preferentially binds Ins(1,4,5)P3 ~10-fold over PI(4,5)P2, whereas PRIP-2 binds both with similar affinity. Northern blot, in situ hybridization, radioligand binding assays, co-immunoprecipitation Life sciences Medium 12467885
2002 PRIP-1 (rat/mouse ortholog of PLCL1) interacts with PP1 catalytic subunit and GABARAP via distinct domains (N-terminus preceding the PH domain for PP1; EF-hand motifs for GABARAP); PRIP-1 inhibits PP1 catalytic activity in a concentration-dependent manner, and competitively inhibits binding of the GABAA receptor γ2 subunit to GABARAP in vitro; PRIP-1 knockout mice show impaired GABAA receptor function. Yeast two-hybrid, pull-down, far-western, immunoprecipitation, surface plasmon resonance, enzymatic activity assay, electrophysiology in knockout mice Nihon yakurigaku zasshi High 11979730
2005 PRIP-1 (PLCL1 ortholog) regulates Ins(1,4,5)P3-mediated Ca2+ signaling by binding Ins(1,4,5)P3 through its PH domain, thereby preventing Ins(1,4,5)P3 hydrolysis; in PRIP-1 knockout neurons, Ca2+ responses and Ins(1,4,5)P3 levels are lower due to enhanced activity of type-1 inositol polyphosphate 5-phosphatase, which PRIP-1 physically interacts with and inhibits. PRIP-1 knockout mouse neurons, Ca2+ imaging, [3H]Ins(1,4,5)P3 labeling, PLC activity assay, in vitro pull-down with PH domain, 5-phosphatase activity assay Journal of cellular physiology High 15468068
2005 PRIP (PLCL1 ortholog) interacts with PP1, PP2A, GABARAP, and the β-subunits of GABAA receptors; PRIP modulates phospho-regulation of GABAA receptor β-subunits through PP1 binding, which is regulated by PKA-dependent phosphorylation of PRIP at threonine 94. Yeast two-hybrid, pull-down with purified proteins, immunoprecipitation, electrophysiology/behavior in double-knockout mice, phosphatase activity assay Molecules and cells High 16404143
2006 PRIP (PLCL1 ortholog) controls dynamics of GABAA receptor β-subunit phosphorylation via PP1: PKA-dependent phosphorylation of PRIP reduces PP1 binding but increases PP2A binding, creating a phospho-dependent switch that regulates the dephosphorylation timing of GABAA receptor β3 subunits; PRIP-1/2 double-knockout mice show altered β3 phosphorylation dynamics. Site-directed mutagenesis, pull-down with purified recombinant proteins, kinase/phosphatase activity assays, cortical neuron culture from double-knockout mice, forskolin stimulation Advances in enzyme regulation High 16854455
2007 PRIP (PLCL1 ortholog) regulates surface expression of GABAA receptors by modulating clathrin/AP2-mediated phospho-regulated endocytosis of the γ2-subunit-containing receptor, acting through its interactions with GABARAP and PP1/PP2A. Review consolidating data from knockout mouse electrophysiology, receptor trafficking assays, immunoprecipitation, phosphatase assays Journal of pharmacological sciences Medium 17690529
2013 PRIP (PLCL1 ortholog) directly interacts with PP1 and PP2A catalytic subunits via distinct but proximal sites; PKA-dependent phosphorylation of PRIP causes dissociation of PP1 and concurrent recruitment of PP2A in a mutually exclusive, phospho-dependent manner both in vitro and in living cells. Pull-down with recombinant proteins, site-directed mutagenesis, immunoprecipitation from neuronal cells, cellular treatment with forskolin/isoproterenol Advances in biological regulation High 23911386
2013 The C2 domain of PRIP (PLCL1 ortholog) directly interacts with syntaxin 1 and SNAP-25 (but not VAMP2), competes with synaptotagmin I for SNAP-25/syntaxin 1 binding, suppresses SDS-resistant ternary SNARE complex formation, and inhibits high-K+-induced noradrenalin exocytosis from PC12 cells. In vitro binding assay, co-immunoprecipitation, PC12 cell overexpression, noradrenalin secretion assay, SNARE complex gel assay The Journal of biological chemistry High 23341457
2012 PRIP (PLCL1 ortholog) modulates SNAP-25 phosphorylation and regulated exocytosis: PRIP binds PP1 (via its PP1-binding site) and promotes dephosphorylation of phospho-SNAP-25 by PP1; PRIP expression in PC12 cells accelerates dephosphorylation of SNAP-25 and reduces noradrenalin secretion after PKA or PKC activation; SNAP-25 and PP1 co-precipitate with PRIP. In vitro dephosphorylation assay with purified proteins, PC12 cell overexpression with noradrenalin secretion, anti-PRIP immunoprecipitation, PP1-binding mutant (F97A) comparison The Journal of biological chemistry High 22311984
2014 PRIP (PLCL1 ortholog) controls KIF5B-mediated insulin secretory vesicle transport by sequestering GABARAP; PRIP knockdown frees GABARAP to associate with insulin vesicles, increasing KIF5B–vesicle co-localization and vesicle mobility, resulting in enhanced insulin secretion from MIN6 cells. siRNA knockdown in MIN6 insulinoma cells, GFP-phogrin live imaging, double immunofluorescence, density gradient fractionation, interference peptide experiments Biology open High 24812354
2014 PRIP (PLCL1 ortholog) promotes translocation of PP2A to lipid droplets in adipocytes in response to adrenaline, facilitating dephosphorylation of hormone-sensitive lipase (HSL) and perilipin A and thereby reducing PKA-mediated lipolysis; PRIP-KO mice show reduced body fat, elevated HSL phosphorylation, reduced PP2A translocation to lipid droplets, and increased lipolysis. PRIP-KO mouse adipose tissue, subcellular fractionation, phospho-HSL western blot, glycerol/NEFA lipolysis assay, phosphatase inhibitor treatment, adrenaline stimulation PloS one High 24945349
2016 PLCL1 (PRIP-1) is induced by progesterone signaling in decidualizing human endometrial stromal cells (HESCs); PRIP-1 maintains basal PI3K/AKT activity (preventing FOX01 nuclear translocation and BIM-mediated apoptosis) in undifferentiated HESCs, and in decidual cells it uncouples PLC activation from intracellular Ca2+ release by attenuating Ins(1,4,5)P3 signaling downstream of Gq-coupled receptors. siRNA knockdown in HESCs, western blot for AKT/FOXO1/BIM, Ca2+ imaging, progesterone treatment, differentiation marker assays Endocrinology High 27167772
2017 PRIP (PLCL1 ortholog) promotes osteoclast differentiation through calcium-calcineurin-NFATc1 signaling: PRIP-KO mice show reduced osteoclast numbers, lower calcineurin expression and activity, reduced M-CSF-induced intracellular Ca2+ changes, and impaired NFATc1 nuclear localization; restoring intracellular Ca2+ rescues osteoclastogenesis in KO cells. PRIP-KO mouse orthodontic tooth movement model, histomorphometry, osteoclast differentiation assay, flow cytometry, Ca2+ imaging, calcineurin activity assay, NFATc1 immunofluorescence The Journal of biological chemistry High 28341745
2011 PRIP (PLCL1 ortholog) negatively regulates bone formation: PRIP-KO mice show increased bone mineral density, elevated osteoblast differentiation markers (alkaline phosphatase, osteogenic genes), and prolonged BMP-induced Smad1/5/8 phosphorylation in calvaria-derived osteoblasts. PRIP-KO mouse 3D femur micro-CT, histomorphometry, primary calvaria osteoblast culture, alkaline phosphatase assay, Smad phosphorylation western blot The Journal of biological chemistry High 21757756
2015 PRIP (PLCL1 ortholog) modulates BMP/Smad signaling in osteoblasts: in PRIP-deficient calvaria cells, BMP-induced Smad1/5 phosphorylation is enhanced; PRIP acts by facilitating methylation (via methyltransferase DB867-sensitive activity) and nuclear retention of inhibitory Smad6, which dampens BMP-receptor signaling. Primary calvaria cell culture from PRIP-KO mice, luciferase assay (Id1 promoter/Smad1 constitutively active), western blot for Smad1/5 phosphorylation, DB867 inhibitor treatment, Smad6 localization by immunofluorescence Journal of cellular biochemistry Medium 25981537
2019 PLCL1 promotes tumor cell 'slimming' in clear cell renal cell carcinoma (ccRCC) by improving the protein stability of UCP1 through reducing UCP1 ubiquitination; PLCL1-mediated UCP1 activation drives lipid browning, consuming lipid droplets without ATP production, and suppresses tumor progression. PLCL1 overexpression/restoration in ccRCC cells, lipid droplet imaging, tumor xenograft, UCP1 protein stability/ubiquitination assay, TCGA bioinformatics Advanced science Medium 31131187
2021 PRIP (PLCL1 ortholog) competes with PI3K for PI(4,5)P2 substrate, thereby attenuating PI3K/AKT/GSK3β signaling, reducing cyclin D1 accumulation, and suppressing cell cycle progression and tumor growth; stable PLCL1/PRIP expression in MCF-7 breast cancer cells reduces AKT/GSK3β phosphorylation and inhibits xenograft tumor growth in mice. PRIP siRNA knockdown and stable overexpression in MCF-7 cells, PI(3,4,5)P3 immunofluorescence, western blot for AKT/GSK3β/cyclin D1, flow cytometry cell cycle analysis, xenograft mouse model Biochemical and biophysical research communications High 33743346
2022 PLCL1 promotes inflammation in rheumatoid arthritis fibroblast-like synoviocytes (FLS) via NLRP3 inflammasome activation: PLCL1 silencing reduces IL-6, IL-1β, and CXCL8 levels after TNF-α stimulation; PLCL1 overexpression increases these cytokines; NLRP3 inhibitor INF39 counteracts the pro-inflammatory effect of PLCL1 overexpression. siRNA knockdown and plasmid overexpression in RA-FLS, TNF-α stimulation, western blot, qPCR, ELISA, NLRP3 inhibitor (INF39) epistasis Advances in rheumatology Medium 35820936
2023 PLCL1 suppresses renal cell carcinoma progression by activating the AMPK/mTOR pathway, inducing autophagy, and promoting apoptosis; PLCL1 interacts with DEPP (decidual protein induced by progesterone) as identified by transcriptional analysis and western blot. Stable PLCL1 overexpression in 786-O cells, wound healing, transwell, flow cytometry, western blot for AMPK/mTOR/autophagy markers, co-immunoprecipitation with DEPP Aging Medium 37801481
2025 LCOR interacts with transcriptional repressor RUNX1 to relieve RUNX1-mediated repression of PLCL1 in ccRCC; PLCL1 in turn inhibits tumor progression and lipid accumulation via UCP1-mediated lipid browning and activates p38 phosphorylation to facilitate apoptosis. Bioinformatics, in vitro/in vivo experiments, LCOR-RUNX1 interaction assay, PLCL1 overexpression/KD in ccRCC cells, p38 phosphorylation western blot, xenograft International journal of biological sciences Medium 40083699
2026 PRIP/PLCL1 deficiency enhances TGF-β1-induced fibroblast activation and organ fibrosis; mechanistically, loss of PRIP activates AKT, promotes MST2 phosphorylation at Thr117, and facilitates nuclear translocation of YAP (Hippo pathway effector), driving profibrotic gene expression; in vivo, PRIP-KO mice show accelerated kidney and heart fibrosis after angiotensin II treatment. Prip-KO mouse angiotensin II fibrosis model, MEF culture with TGF-β1, qPCR, western blot for AKT/MST2/YAP, YAP nuclear localization assay, GSEA bioinformatics Cell communication and signaling High 41680862
2025 Plcl1 is selectively enriched in the most quiescent hematopoietic stem cell (HSC) subset and regulates intracellular calcium dynamics; Plcl1 deficiency reduces basal Ca2+ levels, diminishes calcium-responsive immediate-early gene induction, skews HSCs toward CD41+ subsets at steady state, amplifies platelet rebound and non-canonical megakaryocyte progenitor expansion under stress, and exacerbates aging-associated HSC features. Plcl1-KO mouse model, intracellular Ca2+ imaging in HSCs, flow cytometry, competitive reconstitution assay, gene expression analysis of Ca2+-responsive genes bioRxivpreprint Medium

Source papers

Stage 0 corpus · 94 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1993 Thiamine-repressible expression vectors pREP and pRIP for fission yeast. Gene 970 8422996
2000 Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. The Journal of biological chemistry 161 10788465
2016 3D bioprinting of urethra with PCL/PLCL blend and dual autologous cells in fibrin hydrogel: An in vitro evaluation of biomimetic mechanical property and cell growth environment. Acta biomaterialia 156 27940192
2014 Electrospun gelatin/PCL and collagen/PLCL scaffolds for vascular tissue engineering. International journal of nanomedicine 154 24872696
2005 Mechano-active tissue engineering of vascular smooth muscle using pulsatile perfusion bioreactors and elastic PLCL scaffolds. Biomaterials 130 15482828
2004 Manufacture of elastic biodegradable PLCL scaffolds for mechano-active vascular tissue engineering. Journal of biomaterials science. Polymer edition 110 15264665
1991 APP717, APP693, and PRIP gene mutations are rare in Alzheimer disease. American journal of human genetics 93 1679288
2001 Cloning and characterization of PIMT, a protein with a methyltransferase domain, which interacts with and enhances nuclear receptor coactivator PRIP function. Proceedings of the National Academy of Sciences of the United States of America 86 11517327
2014 Preparation and characterization of electrospun PLCL/Poloxamer nanofibers and dextran/gelatin hydrogels for skin tissue engineering. PloS one 81 25405611
2014 Phenome-wide association study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic Esophagitis. Frontiers in genetics 71 25477900
2002 Coactivator PRIP, the peroxisome proliferator-activated receptor-interacting protein, is a modulator of placental, cardiac, hepatic, and embryonic development. The Journal of biological chemistry 63 12446700
2002 Molecules interacting with PRIP-2, a novel Ins(1,4,5)P3 binding protein type 2: Comparison with PRIP-1. Life sciences 60 12467885
2016 Polymerizing Pyrrole Coated Poly (l-lactic acid-co-ε-caprolactone) (PLCL) Conductive Nanofibrous Conduit Combined with Electric Stimulation for Long-Range Peripheral Nerve Regeneration. Frontiers in molecular neuroscience 58 27877111
2015 Electrospun SF/PLCL nanofibrous membrane: a potential scaffold for retinal progenitor cell proliferation and differentiation. Scientific reports 57 26395224
2019 Tumor Cell "Slimming" Regulates Tumor Progression through PLCL1/UCP1-Mediated Lipid Browning. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 56 31131187
2003 Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor gamma (PPARgamma)-interacting protein, is required for PPARgamma-mediated adipogenesis. The Journal of biological chemistry 54 12754253
2023 Polydopamine-Decorated PLCL Conduit to Induce Synergetic Effect of Electrical Stimulation and Topological Morphology for Peripheral Nerve Regeneration. Small methods 50 36596669
2021 Antibacterial, antioxidant and anti-inflammatory PLCL/gelatin nanofiber membranes to promote wound healing. International journal of biological macromolecules 49 34838860
2012 Composite system of PLCL scaffold and heparin-based hydrogel for regeneration of partial-thickness cartilage defects. Biomacromolecules 48 22758918
2022 Development of a regenerative porous PLCL nerve guidance conduit with swellable hydrogel-based microgrooved surface pattern via 3D printing. Acta biomaterialia 47 35081432
2014 Heparinized PLLA/PLCL nanofibrous scaffold for potential engineering of small-diameter blood vessel: tunable elasticity and anticoagulation property. Journal of biomedical materials research. Part A 47 25196988
2008 Identification of PLCL1 gene for hip bone size variation in females in a genome-wide association study. PloS one 47 18776929
1999 Identification and characterization of a new phospholipase C-like protein, PLC-L(2). Biochemical and biophysical research communications 46 10581172
2018 A 3D-Printed PLCL Scaffold Coated with Collagen Type I and Its Biocompatibility. BioMed research international 40 29850530
2007 Regulation of GABA(A)-receptor surface expression with special reference to the involvement of GABARAP (GABA(A) receptor-associated protein) and PRIP (phospholipase C-related, but catalytically inactive protein). Journal of pharmacological sciences 37 17690529
2022 Surface-Modified Polypyrrole-Coated PLCL and PLGA Nerve Guide Conduits Fabricated by 3D Printing and Electrospinning. Biomacromolecules 35 36169096
2015 TGF-β3 encapsulated PLCL scaffold by a supercritical CO2-HFIP co-solvent system for cartilage tissue engineering. Journal of controlled release : official journal of the Controlled Release Society 33 25804870
2005 Role of PRIP-1, a novel Ins(1,4,5)P3 binding protein, in Ins(1,4,5)P3-mediated Ca2+ signaling. Journal of cellular physiology 28 15468068
2016 Progesterone-Dependent Induction of Phospholipase C-Related Catalytically Inactive Protein 1 (PRIP-1) in Decidualizing Human Endometrial Stromal Cells. Endocrinology 27 27167772
2006 Fabrication of a new tubular fibrous PLCL scaffold for vascular tissue engineering. Journal of biomaterials science. Polymer edition 27 17260508
1990 A codon 129 polymorphism in the PRIP gene. Nucleic acids research 25 1971924
2017 Clinical significance of the correlation between PLCE 1 and PRKCA in esophageal inflammation and esophageal carcinoma. Oncotarget 24 28402280
2017 Dual-delivery of FGF-2/CTGF from Silk Fibroin/PLCL-PEO Coaxial Fibers Enhances MSC Proliferation and Fibrogenesis. Scientific reports 24 28819120
2014 Phospholipase C-related catalytically inactive protein (PRIP) regulates lipolysis in adipose tissue by modulating the phosphorylation of hormone-sensitive lipase. PloS one 24 24945349
2018 Mesenchymal stem cell interacted with PLCL braided scaffold coated with poly-l-lysine/hyaluronic acid for ligament tissue engineering. Journal of biomedical materials research. Part A 23 30194699
2005 PRIP, a novel Ins(1,4,5)P3 binding protein, functional significance in Ca2+ signaling and extension to neuroscience and beyond. Molecules and cells 23 16404143
2012 Phospholipase C-related but catalytically inactive protein (PRIP) modulates synaptosomal-associated protein 25 (SNAP-25) phosphorylation and exocytosis. The Journal of biological chemistry 21 22311984
2006 Peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP) but not PPAR-interacting protein (PRIP) is required for nuclear translocation of constitutive androstane receptor in mouse liver. Biochemical and biophysical research communications 21 16828057
2006 Protein phosphatase regulation by PRIP, a PLC-related catalytically inactive protein--implications in the phospho-modulation of the GABAA receptor. Advances in enzyme regulation 20 16854455
2014 Phospholipase C-related catalytically inactive protein (PRIP) controls KIF5B-mediated insulin secretion. Biology open 19 24812354
2013 PLCɛ and the RASSF family in tumour suppression and other functions. Advances in biological regulation 19 23958207
2003 Different isoforms of PRIP-interacting protein with methyltransferase domain/trimethylguanosine synthase localizes to the cytoplasm and nucleus. Biochemical and biophysical research communications 19 12943661
2013 PRIP (phospholipase C-related but catalytically inactive protein) inhibits exocytosis by direct interactions with syntaxin 1 and SNAP-25 through its C2 domain. The Journal of biological chemistry 17 23341457
2008 Fabrication of collagen hybridized elastic PLCL for tissue engineering. Biotechnology letters 17 18661107
2005 A sex pheromone, protoplast release-inducing protein (PR-IP) inducer, induces sexual cell division and production of PR-IP in Closterium. Plant & cell physiology 17 15970600
2013 Phospholipase C-related but catalytically inactive protein, PRIP as a scaffolding protein for phospho-regulation. Advances in biological regulation 16 23911386
2022 PLCL1 regulates fibroblast-like synoviocytes inflammation via NLRP3 inflammasomes in rheumatoid arthritis. Advances in rheumatology (London, England) 15 35820936
2021 Substance P/Heparin-Conjugated PLCL Mitigate Acute Gliosis on Neural Implants and Improve Neuronal Regeneration via Recruitment of Neural Stem Cells. Advanced healthcare materials 15 34227258
2017 CRISPR/Cas9-based knockouts reveal that CpRLP1 is a negative regulator of the sex pheromone PR-IP in the Closterium peracerosum-strigosum-littorale complex. Scientific reports 15 29259295
2023 PLCL/PCL Dressings with Platelet Lysate and Growth Factors Embedded in Fibrin for Chronic Wound Regeneration. International journal of nanomedicine 14 36760757
2023 PLCL1 suppresses tumour progression by regulating AMPK/mTOR-mediated autophagy in renal cell carcinoma. Aging 13 37801481
2023 Bioinspired PLCL/Elastin Nanofibrous Vascular Tissue Engineering Scaffold Enhances Endothelial Cells and Inhibits Smooth Muscle Cells. Biomacromolecules 12 37222588
2017 Phospholipase C-related, but catalytically inactive protein (PRIP) up-regulates osteoclast differentiation via calcium-calcineurin-NFATc1 signaling. The Journal of biological chemistry 12 28341745
2015 Biocompatibility Assessment of PLCL-Sericin Copolymer Membranes Using Wharton's Jelly Mesenchymal Stem Cells. Stem cells international 12 26839562
2023 Periodontal bone regeneration with a degradable thermoplastic HA/PLCL bone graft. Journal of materials chemistry. B 11 36444735
2023 Fabrication and performance evaluation of PLCL-hCOLIII small-diameter vascular grafts crosslinked with procyanidins. International journal of biological macromolecules 11 37591423
2017 Development and characterization of hybrid tubular structure of PLCL porous scaffold with hMSCs/ECs cell sheet. Journal of materials science. Materials in medicine 11 28914404
2024 PLCL/SF/NGF nerve conduit loaded with RGD-TA-PPY hydrogel promotes regeneration of sciatic nerve defects in rats through PI3K/AKT signalling pathways. Journal of cellular and molecular medicine 10 39098996
2023 Engineering a conduction-consistent cardiac patch with rGO/PLCL electrospun nanofibrous membranes and human iPSC-derived cardiomyocytes. Frontiers in bioengineering and biotechnology 10 36845196
2019 Injectable PLCL/gelatin core-shell nanofibers support noninvasive 3D delivery of stem cells. International journal of pharmaceutics 10 31352047
2016 Di-Block PLCL and Tri-Block PLCLG Matrix Polymeric Nanoparticles Enhanced the Anticancer Activity of Loaded 5-Fluorouracil. IEEE transactions on nanobioscience 10 28029617
2022 Synthesis and Characterization of PU/PLCL/CMCS Electrospun Scaffolds for Skin Tissue Engineering. Polymers 9 36433156
2021 The role of biomechanical forces and MALAT1/miR-329-5p/PRIP signalling on glucocorticoid-induced osteonecrosis of the femoral head. Journal of cellular and molecular medicine 9 33939272
2020 PLCɛ maintains the functionality of AR signaling in prostate cancer via an autophagy-dependent mechanism. Cell death & disease 9 32879302
2016 Characterization of Tensile Mechanical Behavior of MSCs/PLCL Hybrid Layered Sheet. Journal of functional biomaterials 9 27271675
2011 Involvement of PRIP, phospholipase C-related, but catalytically inactive protein, in bone formation. The Journal of biological chemistry 9 21757756
2007 Transcription coactivator PRIP, the peroxisome proliferator-activated receptor (PPAR)-interacting protein, is redundant for the function of nuclear receptors PParalpha and CAR, the constitutive androstane receptor, in mouse liver. Gene expression 9 17605299
2024 The Combination of Aligned PDA-Fe@PLCL Conduit with Aligned GelMA Hydrogel Promotes Peripheral Nerve Regeneration. Advanced healthcare materials 8 39718234
2021 Expression of PRIP, a phosphatidylinositol 4,5-bisphosphate binding protein, attenuates PI3K/AKT signaling and suppresses tumor growth in a xenograft mouse model. Biochemical and biophysical research communications 8 33743346
2019 Characterisation and in vitro and in vivo evaluation of supercritical-CO2-foamed β-TCP/PLCL composites for bone applications. European cells & materials 8 31381126
2009 PRIP promotes tumor formation through enhancing serum-responsive factor-mediated FOS expression. The Journal of biological chemistry 8 19329434
2024 Preparation of PLCL/ECM nerve conduits by electrostatic spinning technique and evaluationin vitroandin vivo. Journal of neural engineering 7 38572924
2019 Preparation and characteristics of electrospinning PTH-Fc/PLCL/SF membranes for bioengineering applications. Journal of biomedical materials research. Part A 7 31566865
2020 Characterization of Bone Marrow and Wharton's Jelly Mesenchymal Stromal Cells Response on Multilayer Braided Silk and Silk/PLCL Scaffolds for Ligament Tissue Engineering. Polymers 6 32971891
2020 Efficient co-cultivation of human fibroblast cells (HFCs) and adipose-derived stem cells (ADSs) on gelatin/PLCL nanofiber. IET nanobiotechnology 5 31935681
2018 Biocompatibility and osteoconductivity of PLCL coated and noncoated xenografts: An in vitro and preclinical trial. Clinical implant dentistry and related research 5 29508553
2023 Regulation of Aquaporin Prip Expression and Its Physiological Function in Rhyzopertha dominica (Coleoptera: Bostrichidae). Insects 4 36661998
2023 Promotion of adipose stem cell transplantation using GelMA hydrogel reinforced by PLCL/ADM short nanofibers. Biomedical materials (Bristol, England) 4 37647920
2015 Involvement of PRIP (Phospholipase C-Related But Catalytically Inactive Protein) in BMP-Induced Smad Signaling in Osteoblast Differentiation. Journal of cellular biochemistry 4 25981537
2012 Mechanical properties evolution of a PLGA-PLCL composite scaffold for ligament tissue engineering under static and cyclic traction-torsion in vitro culture conditions. Journal of biomaterials science. Polymer edition 4 23647247
2022 Complex Inheritance of Rare Missense Variants in PAK2, TAP2, and PLCL1 Genes in a Consanguineous Arab Family With Multiple Autoimmune Diseases Including Celiac Disease. Frontiers in pediatrics 3 35783297
2006 Characterization of the human PRIP-1 gene structure and transcriptional regulation. Gene 3 16952428
2022 PRIP: A Protein-RNA Interface Predictor Based on Semantics of Sequences. Life (Basel, Switzerland) 2 35207594
2022 [Biocompatibility evaluation of electrospun PLCL/fibrinogen nanofibers in anterior cruciate ligament reconstruction]. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 2 35788524
2025 Identification of the LCOR-PLCL1 pathway that restrains lipid accumulation and tumor progression in clear cell renal cell carcinoma. International journal of biological sciences 1 40083699
2025 Preparation, Physicochemical Characterization, and In Vitro and In Vivo Osteogenic Evaluation of Reinforced PLLA-PLCL/HA Resorbable Membranes. Journal of biomedical materials research. Part A 1 40334262
2025 Modulating Surface Properties and Osteoblast Responses in Bone Regeneration via Positive and Negative Charges during Electrospinning of Poly(l-lactide-co-ε-caprolactone) (PLCL) Scaffolds. ACS biomaterials science & engineering 1 41309068
2024 RBPMS-AS1 sponges miR-19a-3p to restrain cervical cancer cells via enhancing PLCL1-mediated pyroptosis. Biotechnology and applied biochemistry 1 39300709
2002 [The analysis of protein-protein interaction with special reference to PRIP-1]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 1 11979730
2026 PRIP/PLCL deficiency activates PI3K-AKT-YAP signaling and promotes organ fibrosis. Cell communication and signaling : CCS 0 41680862
2026 Biological and Biophysical Characterization of Hybrid PLCL Nanofibers Incorporating Stem Cell-Derived Secretome. Polymers 0 41754720
2025 PPDO-induced tunable degradation and HA-enhanced osteogenesis in PLCL scaffolds for bone regeneration. Journal of biomaterials science. Polymer edition 0 40523307
2025 The endothelial layer formation in the presence of AuNPs/CdSe/TaNPs-loaded PLCL/PVP-based electrospun nanofibers. Frontiers in molecular biosciences 0 40900915
2025 Comparative Physicochemical Characterization of Electrospun PCL, PLLA, and PLCL Scaffolds and Cell Responses for Tissue Engineering Applications. Macromolecular bioscience 0 41401356